Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

Completed

• Conditions: Breast Cancer

• Registration Number: NCT01081509
• Lead Sponsor: AstraZeneca

Brief Summary

The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03
• Study First Submitted: 2010-03-04
• Study First Submitted QC: 2010-03-04
• Study First Posted: 2010-03-05
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2011-11
• Last Update Submitted: 2011-11-15
• Last Update Posted: 2011-11-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 1077

Inclusion Criteria

• Early breast cancer
• Post menopausal
• Adjuvant hormonal Arimidex therapy

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percent of patients remaining adherent to therapy with Arimidex	Every 3 months

Secondary Outcome Measures

Name	Time	Method
Questionnaire for factors influencing adherence	Every 3 months

Trial Locations

Locations (1)

Research Site; 🇭🇺 Zirc, Hungary